News Article | May 11, 2017
-- Although Medicare began paying for chronic care management (CCM) services in 2016, the Centers for Medicare and Medicaid Services (CMS) reports that many practices are not taking advantage of the new coverage, even after more than a year. And if you're not billing this service for those who are likely your sickest patients, you're losing out on significant reimbursement.When your practitioner provides CCM services, he manages a patient's medical, functional and psychosocial needs. This includes spending at least 20 minutes each month on things like medication management and coordinating other therapeutic services. Your office also becomes the point of contact for patients and their caregivers not only through telephone access, but also via secure messaging, Internet or other non-face-to-face consultation. Your office has to be able to provide these services any time of day or night to qualify for CCM reimbursement (either via your in-house staff or a third party).If your clinician(s)documents the service correctly and you properly apply CCM code 99490, Medicare will reimburse your office for this time at a rate of roughly $42 for each patient per 30-day period in 2017. Although this doesn't sound like much, it can quickly add up. For instance, if you provide CCM services to 100 Medicare patients each month, and code these services based on CCM guidelines, you could bring in $42,000 extra per year. Also, you can bill for other services in addition to CCM, which means this reimbursement is on top of what you normally receive.For example, an elderly patient with multiple illnesses and dementia bound for a nursing home can have as many as 10 different doctors — half of whom may be prescribing medications. Patients and their families find dealing with so many different specialists bewildering and stressful. At the same time, CMS believes that its payers spend more than two-thirds of Medicare dollars on these patients.CCM is meant to address this situation by helping to:• Manage these different providers' care.• Ensure all medication prescribed makes sense for the patient when• taken together.• Reduce the expense of uncoordinated services by paying one primary care physician to serve as the point of contact for all the patient's care.For 2017, CMS will also pay for complex chronic care management with codes 99487 and +99489. You can find out more about coding and billing for this service in a previous blog ( https://codingleader.com/ blogs/compliancepop/ ccm-2017 ) and in Coding Leader's Chronic Care Management Coding 2017 Expert Report ( https://codingleader.com/ products/chronic- care-management... ).So if you've chalked up CCM as more trouble than it's worth, you might want to reconsider what these services could mean for your practice. In many cases, you may find that you're already performing this level of service, and you should be reimbursed accordingly.• If you're providing at least 20 minutes of chronic care management services, you should be reporting them with 99490.• Patients and their families prefer to have a single point of contact for their care, and this could be a significant income for your practice.• CCM can improve patient care and safety by coordinating the efforts of multiple providers and reducing duplicated or contradictory services.For more strategies for effectively addressing chronic care management related challenges, check out Coding Leader's online training session — Chronic Care Management 2017 CPT Coding Update (https://codingleader.com/products/2017-ccm-update). And you can view all upcoming live online training sessions at https://codingleader.com/pages/online-training-calendar.
News Article | May 9, 2017
OrthAlign, Inc., a privately held U.S.-based medical device and technology company providing orthopedic surgeons with advanced precision technologies, announced today the appointment of Andy Turner as Country Director of Australia and New Zealand to support continued growth and investment of OrthAlign technologies in that region of the world. He will be based in Sydney. Andy has over twenty years experience in the orthopaedic industry, in both the sales and marketing functions. His career began in Europe with DePuy, followed by a move to Biomet, where he was responsible for launching the Vanguard knee system across Europe. Andy moved to Australia in 2008 and has held senior management and executive positions for Smith & Nephew and ZimmerBiomet, where he was responsible for marketing, sales, and product management of the orthopedic portfolios. During his career, he has successfully managed some of the largest global orthopedic brands, namely, Legion, CPCS, Polar, NexGen, Oxford, and CPT, respectively. Andy’s strong commercial acumen and sales drive has resulted in meeting corporate objectives and financial targets at every stage of his career. He holds an Honors Degree in Management with a Major in Physiology from Hallam University, Sheffield, UK. “The addition of Andy as a local leader for OrthAlign in Australia and New Zealand is just one of many major investments that we are making in those very important markets. KneeAlign® has already established itself as one of the leading orthopaedic technologies in ANZ, but OrthAlign technology is just scratching the surface," said James Young Kim, OrthAlign’s Vice President and General Manager of International. "Andy's local presence will greatly enhance our continued efforts in customer expansion, growth in our portfolio of products, and focus in providing world class customer service to our surgeons, hospitals, and surgery centers. With 65,000 knee and 45,000 hip arthroplasties completed in Australia and New Zealand in 2016, we are excited about the growth opportunities that are before us.” OrthAlign is a privately held medical device and technology company, developing advanced technologies that deliver healthier and more pain-free lifestyles to joint replacement patients, globally. We provide healthcare professionals with cutting edge, computer-assisted surgical tools that seamlessly and cost-effectively deliver vital data and clinical results to optimize outcomes for our patients. For more information regarding OrthAlign, please visit http://www.orthalign.com. “ORTHALIGN®, ORTHALIGN PLUS®, KNEEALIGN®, KNEEALIGN® 2, HIPALIGN®, and UNIALIGN™ are registered trademarks of OrthAlign, Inc.”
News Article | May 9, 2017
Two Studies Presented at DDW 2017 Showed Clinically Meaningful Reduction in Symptoms and Withdrawal or Reduction in Proton Pump Inhibitor Use by Two-Thirds of Patients Following Treatment with MUSE™ System Separate Presentation Supports HOF Criteria as a Potential Endoscopic Selection Criteria to Predict Amount of Reflux and Improve Treatment Outcomes OMER, ISRAEL--(Marketwired - May 9, 2017) - Medigus Ltd. ( : MDGS) ( : MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, today announced results from three clinical studies involving the company's MUSE™ System, a minimally invasive solution for gastroesophageal reflux disease (GERD). The data were presented in three posters at Digestive Disease Week® (DDW), taking place in Chicago from May 6-9, 2017. The MUSE system is a single-use flexible transoral stapler that merges the latest advancements in microvisual, ultrasonic and surgical stapling. The device comes equipped with an ultrasonic sight and range finder and a micro ScoutCam™ CMOS camera, which enables a single physician to perform an incisionless transoral fundoplication -- the procedure is intended to treat the anatomical cause of gastroesophageal reflux disease (GERD), commonly known as acid reflux. Giorgia Mazzoleni, fellow at the San Raffaele Scientific Institute at the San Raffaele Hospital in Milan, Italy, presented a poster entitled, "Transoral Anterior Fundoplication (TAF) with Medigus Ultrasound Surgical Endostapler (MUSE™) for the Treatment of Gastroesophageal Reflux Disease (GERD); 6-Month Results from a Single-Center Prospective Study," which enrolled 24 GERD patients to assess the six-month safety and efficacy of TAF with MUSE. GERD quality of life questionnaires (HRQL) improved from a baseline of 43 to 18 six months after TAF with MUSE (p < 0.003). The study also highlighted an improvement in Reflux Symptom Index (RSI), from 21 to 10 (p < 0.009). A 79% reduction or withdrawal in PPI therapy was observed six-months after treatment, with 50% of patients stopping PPI use, 28.6% of patients halving PPI use, and 21.4% remaining on the same dose prior to treatment with TAF with MUSE. Dr. Ali Lankarani, board member of the Advanced Therapeutic Endoscopy Center (ATEC) at the Broland-Groover Clinic in Jacksonville, FL, presented a poster titled, "Interim Results From A Multi-Center Post-Marketing Surveillance Registry Study for Endoscopic Anterior Fundoplication," reported data from an ongoing post-market registry study of 68 GERD patients who underwent Endoscopic Anterior Fundoplication (EAF) in 13 international centers. GERD-HRQL improved from 24.0 to 6.0 following treatment with MUSE (CI, 13.4 - 20.8, p < 0.00001), demonstrating patients experienced a clinically meaningful reduction in GERD-related symptoms. In addition, baseline patient satisfaction was reported at 0%, but improved to 70% (26/37) at 6 months and 90% (9/10) at 1 year. Of note, 76% (28/37; p < 0.00001) of patients have eliminated or reduced their use of proton pump inhibitors (PPI), with 96% of patients that responded favorably to treatment with the MUSE System stopping daily PPI therapy. Dr. Lankarani remarked, "These interim results, in conjunction with the data from the single-center study presented by Mazzoleni, highlight how the MUSE System can be a revolutionary, minimally-invasive treatment option for patients with GERD who are unsatisfied with PPI therapeutics and hesitant to pursue surgical intervention. In addition to the impressive findings, in another study we were able to access the value of the HOF criteria over the Hill classification, which we believe will play a pivotal role alongside the MUSE System in improving overall treatment outcomes in GERD." In addition, Dr. Lankarani presented a second poster, entitled, "Endoscopic Predictors of Decreased Reflux After Endoscopic Anterior Fundoplasty," which evaluated the HOF criteria as an endoscopic grading system of gastroesophageal junction (GEJ) geometry, as well as selection criteria to guide treatment decisions and predict treatment outcomes. Currently, Hill classification is the most commonly used criteria for antireflux procedures, however it has limited utility and still results in one-third of EAF-treated patients to continue experiencing reflux. HOF criteria categorizes GEJ geometry based on measurement of axial length of hiatal hernia (H), hiatus opening dimension (O) and flap valve size (F), with H and O openings less than 1cm considered normal (N) and 1cm or larger categorized as abnormal (A). GEJ is categorized as AAA if all three HOF landmarks are abnormal, NAA if one HOF landmark is normal and two are abnormal, and NNN if all three HOF landmarks are normal. Using the HOF criteria, the researchers identified and successfully treated 18 GERD patients, with Total Present of Time spent in Reflux (TPTR) showing a reduction in all patients with NAA configuration, and 75% and 71% TPTR reduction in individuals that had a 1 and 2 cm hiatal hernia, respectively. Average TPTR improvement was 53% for the NAA configuration patients, while average TPTR improvement in patients with 1 and 2 cm hiatal hernia was 56% and 46%, respectively. Chris Rowland, Chief Executive Officer of Medigus, commented, "As the developers of a completely new, minimally invasive solution for the treatment of GERD, we are extremely motivated by data presented this year at DDW. We are pleased with the results reported from the single center study, and look forward to continuing the ongoing post-market multi-center study, which have shown promising reductions in PPI reliance, as well as increases in patient quality of life and satisfaction. These studies continue to support the use of our MUSE System, which can reduce the need for pharmaceuticals and invasive surgical procedures." To learn more about MUSE, visit: www.medigus.com Medigus is a medical device company specializing in developing minimally invasive endosurgical tools and highly innovative imaging solutions. They are the pioneer developer of the MUSE™ system, an FDA cleared and CE marked endoscopic device to perform Transoral Fundoplication (TF) for the treatment of GERD (gastroesophageal reflux disease), one of the most common chronic conditions in the world. In 2016, the CMS established the Category I CPT® Code of 43210 for TF procedures, such as the ones performed with MUSE, which establishes reimbursement values for physicians and hospitals. MUSE is gaining adoption in key markets around the world -- it is available in world-leading healthcare institutions in the U.S., Europe and Israel. Medigus is also in the process of obtaining regulatory clearance in China. Medigus is traded on the Nasdaq Capital Market and the TASE (Tel-Aviv Stock Exchange). To learn more about the company's advanced technology, please visit www.medigus.com or www.RefluxHelp.com. This press release may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions and expectations of the company's management and its knowledge of the relevant market. The company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These forward-looking statements represent Medigus' expectations or beliefs concerning future events, and it is possible that the results described in this news release will not be achieved. By their nature, Forward-Looking Statements involve known and unknown risks, uncertainties and other factors which may cause future results of the company's activity to differ significantly from the content and implications of such statements. Other risk factors affecting the company are discussed in detail in the Company's filings with the Securities and Exchange Commission. Forward-Looking Statements are pertinent only as of the date on which they are made, and the company undertakes no obligation to update or revise any Forward-Looking Statements, whether as a result of new information, future developments or otherwise. Neither the company nor its shareholders, officers and employees, shall be liable for any action and the results of any action taken by any person based on the information contained herein, including without limitation the purchase or sale of company securities. Nothing in this press release should be deemed to be medical or other advice of any kind.
News Article | May 10, 2017
BILLERICA, Mass--(BUSINESS WIRE)--SRS Medical, Inc., announced today the publication of additional clinical efficacy data on the use of its Spanner® Temporary Prostate Stent. The Canadian Journal of Urology published the clinical results of 214 stent placements in male patients with symptoms of benign prostatic hyperplasia (BPH). The findings affirm that the fully-internal device effectively restores natural urination with a low infection rate and high patient quality of life. Data showed that The Spanner allowed patients to maintain natural urination, reducing the measure of urine remaining in the bladder after void by 81%. Each device was implanted for 30 days, with six of 214 placements resulting in a symptomatic urinary tract infection (0.93 infections per 1,000 stent days). In comparison to published data on chronically catheterized male patients, Spanner patients demonstrated a greater than 75% reduction in symptomatic infection rate as compared to indwelling catheter patients. “Our patients are having remarkable clinical success with The Spanner,” said Richard Roach, MD, author of the study and partner at Advanced Urology Institute of Oxford, FL. “Men who transition to the stent are often able to break the cycle of urinary tract infections caused by catheter use. In addition, eliminating the catheter has a profound impact on the patient’s medical condition and overall health.” Unlike urinary catheters, The Spanner does not require external components to enable bladder drainage. Instead, a completely internal design permits The Spanner to stent the prostate while maintaining urinary continence. The device preserves natural voiding habits, often with no device awareness, and reduces exposure to potentially harmful bacteria in the surrounding environment. “The Spanner Stent is a significantly better clinical solution than a urinary catheter for most male retention patients,” said Lee Brody, CEO of SRS Medical. “The stent offers a higher quality of life, with lower complication rates, including the elimination of most urinary tract infections caused by catheter use. The high efficacy reported in the recent peer-reviewed literature is consistent with the clinical successes that our urologist clients and their patients are experiencing around the world.” The Spanner Temporary Prostatic Stent is CE marked and an FDA-approved Class III medical device intended to maintain urine flow and allow for voluntary urination in certain male patients experiencing lower urinary tract symptoms (LUTS). The device consists of two anchors and a silicone tube that reduces resistance in the bladder neck and prostatic urethra without stenting the external sphincter. The Spanner is placed blindly without anesthesia, in a procedure similar to the placement of a Foley catheter. The Spanner is reimbursed under CPT Code 53855. SRS Medical is dedicated to improving the health and well-being of men experiencing LUTS. The company, based in Billerica, Mass., does this by delivering innovative, cost-effective tools to urologists, enabling them to better diagnose and treat these patients. For more information about SRS Medical: www.srsmedical.com.
News Article | May 12, 2017
Houston, Texas headquartered Camden Property Trust's stock edged 0.48% lower, to close the day at $81.70. The stock recorded a trading volume of 480,542 shares. Camden Property Trust's shares have advanced 0.31% in the previous three months and 4.03% in the past one year. The Company's shares are trading 0.62% and 1.56% above its 50-day and 200-day moving averages, respectively. Shares of the Company, which invests in the real estate markets of the US, are trading at a PE ratio of 17.07. Additionally, the stock has a Relative Strength Index (RSI) of 50.63. CPT complete research report is just a click away and free at: On Thursday, shares in US-based Independence Realty Trust Inc. ended the session 0.55% lower at $9.02, with a total volume of 293,050 shares traded. Independence Realty Trust's shares have gained 17.14% in the past one year. Shares of the Company, which makes investments in apartment properties to create its portfolio, are trading at a PE ratio of 80.54. The stock is trading 1.92% below its 50-day moving average and 0.90% below its 200-day moving average. Moreover, the Company's shares have an RSI of 44.22. The complimentary report on IRT can be downloaded at: On Thursday, shares in Vero Beach, Florida-based ARMOUR Residential REIT Inc. recorded a trading volume of 257,724 shares. The stock ended the day 1.04% lower at $24.82. ARMOUR Residential REIT Inc.'s stock has advanced 5.39% in the last one month and 14.06% in the previous three months. Furthermore, the stock has gained 21.19% in the past one year. The Company's shares are trading above its 50-day and 200-day moving averages by 7.15% and 10.92%, respectively. Furthermore, shares of ARMOUR Residential REIT, which invests in residential mortgage backed securities in the US, are trading at a PE ratio of 3.36. The stock has an RSI of 61.03. Sign up for your complimentary research report on ARR at: Memphis, Tennessee-based EdR's stock finished Thursday's session 1.03% lower at $37.54, with a total volume of 440,201 shares traded. The Company's shares are trading below its 50-day and 200-day moving averages by 4.90% and 8.56%, respectively. Shares of EdR, which develops, acquires, owns, and manages collegiate housing communities located near university campuses, are trading at a PE ratio of 84.55. The stock has an RSI of 39.05. On May 02nd, 2017, research firm Canaccord Genuity reiterated its 'Hold' rating on the Company's stock with a decrease of the target price from $43 a share to $42 a share. Get free access to your research report on EDR at: Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. SC has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
News Article | May 9, 2017
Most patients with hepatitis C virus can be cured by direct-acting antiviral agents (DAAs), but some with the more serious decompensated cirrhosis fail to improve or experience further deterioration even after treatment. Dr. Dunn's team focused on the Rs738409 single nucleotide polymorphism, which is a variation in a single base pair of DNA in the PNPLA3 gene; patients possess one of three genotypes — CC, CG, or GG. The PNPLA3 gene is the most important genetic risk factor for both alcoholic liver disease and nonalcoholic fatty liver disease. The team followed 32 patients with decompensated cirrhosis who had initially achieved sustained virologic response (SVR). They had become essentially virus-free, using interferon-free DAAs. Twelve to 48 weeks after SVR, researchers tracked changes in the Model for End-Stage Liver Disease (MELD) and the Child-Pugh (CPT) scores, measures that assess the severity of chronic liver disease. Following DAA treatment, researchers found that five of the 16 patients with the CG or GG genotypes experienced worsened MELD or CPT scores. In comparison, only one patient with the CC genotype worsened in either score. "These findings suggest screening for the Rs738409 CG and GG genotypes in hepatitis C patients with decompensated cirrhosis can help to identify individuals who are less likely to recover after achieving a 'cure' of their hepatitis C," added Dr. Dunn. Financial support for this study was provided by the Frontiers Pilot and Collaborative Studies Funding Program. Digestive Disease Week (DDW) 2017 is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. More information can be found at www.ddw.org. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/study-identifies-genetic-markers-that-predict-which-patients-with-hepatitis-c-and-cirrhosis-will-improve-with-treatment-300454288.html
News Article | May 16, 2017
The global urinary slings market to grow at a CAGR of 10.12% during the period 2017-2021. The report, Global Urinary Slings Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market. One trend in market is improving reimbursement policies. Urinary incontinence care management products are generally costly, requiring patients to spend substantially on its treatment. This can be an economic burden, as many insurance policies do not cover such products. Globally, countries are framing reimbursement policies for urinary sling procedures. For example, developed countries, such as the US, provide insurance cover for these products that is likely to create more demand for urinary slings as more people will be able to afford urinary sling surgeries. Over the past few years, there has been a favorable upgrade in Medicare (the official website of the US Government for medical health-related information) reimbursement in the US. Medicare pays physicians for services based on the submission of a claim using one or more specific Current Procedural Terminology (CPT) codes. Each CPT code has a Relative Value Unit (RVU) assigned to it, which when multiplied by the conversion factor and a geographical adjustment creates the compensation rate for a particular service. According to the report, one driver in market is rise in geriatric population. A rising concern worldwide is the aging population in major countries, such as Japan, South Korea, China, Germany, and the US. An aging population means an increase in the number of people suffering from a wide range of chronic diseases, some that cause urinary incontinence. With an increase in aging population, there is also an increase in the number of urinary incontinence cases that requires proper treatment, such as urinary sling surgeries, and this provides a massive opportunity for the vendors in the market. The global adult incontinence market has grown by over 40% in the last five years, which propels the demand for developing innovative urinary slings that can ease the handling of the medical condition faced by the elderly population. PART 01: Executive summary PART 02: Scope of the report PART 03: Market research methodology PART 04: Introduction PART 05: Market landscape PART 06: Market segmentation by product PART 07: Geographical segmentation PART 08: Market drivers PART 09: Impact of drivers PART 10: Market challenges PART 11: Impact of drivers and challenges PART 12: Market trends PART 13: Vendor landscape PART 14: Appendix For more information about this report visit http://www.researchandmarkets.com/research/xbb73p/global_urinary To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/research-and-markets---global-urinary-slings-market-to-grow-at-a-cagr-of-1012-by-2021---key-vendors-are-c-r-bard-boston-scientific-american-medical-systems--coloplast-300458335.html
News Article | May 17, 2017
DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "US Market Report for MIS Sacroiliac Joint Fusion 2017 - MedCore" report to their offering. Sacroiliac (SI) joint dysfunction was once thought to be a less common cause for lower back pain. However, recent studies have shown that SI joint dysfunction (SIJD) may be responsible for up to 30% to 35% of lower back pain. Growth of this spinal treatment has historically been limited by the diagnosis process. One important factor in the future growth of the sacroiliac joint fusion market is the new information surrounding adjacent segment disease. Following a lumbar fusion procedure, whether it was or was not the primary cause of the low back pain, a significant proportion of patients eventually note discomfort or pain in the low back. This can be attributed to the effects of the lumbar fusion, which leads to heightened levels of stress and motion across the sacroiliac joint. Previous analyses of this market expected considerably more growth following the reimbursement changes and CPT code changes of 2014 and 2015, respectively. However, the high level of demand for treatment from the suspected backlog of patients did not materialize as many in the industry had hoped. Nevertheless, rapid growth is still expected, driven by increasing awareness and product availability. For more information about this report visit http://www.researchandmarkets.com/research/35grb5/us_market_report
News Article | May 15, 2017
OMER, ISRAEL--(Marketwired - May 15, 2017) - Medigus Ltd. ( : MDGS) ( : MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, announced today that it has received a Patent from the Japanese Patent Office as well as a Notice of Intention to Grant Patents from the European Patent Office (EPO) for the micro ScoutCam™ miniature camera technology. The micro ScoutCam portfolio of products includes a range of video cameras with small diameter heads that use CMOS (complementary metal oxide semiconductor) or CCD (charge coupled device) based sensors. Japanese Patent No. 6114377 Patent application submitted under title: INTEGRATED ENDOSCOPE IRRIGATION Patent valid until: September 16, 2030 Patent details: As granted it will be the first patent Medigus receives for integrated endoscope irrigation. As granted it refers to the empty spaces between the inner components of an endoscope that are utilized as a channel that enables liquid or gas to flow from the handle section to the distal tip. EPO Patent #1 Patent application submitted under title: SMALL DIAMETER VISUALIZATION PROBES Patent valid until: September 16, 2030 Patent details: Once granted it will refer to small diameter visualization probes where their maximum outer diameter is 2.8mm. EPO Patent #2 Patent application submitted under title: SMALL DIMATER MEDICAL DEVICES CONTAINING VISUALIZATION MEANS Patent valid until: September 16, 2030 Patent details: Once granted it will refer to small diameter medical devices containing visualization means where their maximum diameter is 3.2mm Once both applications are granted they will reinforce the first patent no. 2,478,693 that Medigus received from the EPO on April 19, 2017 for a video camera with a diameter of 1.1mm or less that was allowed on last November 2016. "We are pleased with this notice from the Japanese and European Patent Offices as it validates the significance of our microvisual technology over a variety of applications and builds to our growing body of IP," said Chris Rowland, CEO of Medigus. "Our engineers are continually enhancing our technology platform and remain committed to delivering the most innovative new solutions for a broad scale of unmet needs across medical, industrial and other scientific applications." Medigus also has additional patent applications for integrated endoscope irrigation technology pending at Canada, EPO, Israel, the United States and Korea. Medigus holds existing patents for one of its micro ScoutCam brands as well as for MUSE™, its flagship medical device that incorporates the micro ScoutCam to help physicians perform transoral incisionless fundoplication procedures. About the micro ScoutCam™ Portfolio As an expert in micro-endoscopic devices, Medigus developed the micro ScoutCam™ portfolio, which consists of a variety of micro CMOS and CCD video cameras, and includes micro ScoutCam™ 1.2, which to the best of the company's knowledge, is the smallest in the world. micro ScoutCam technology features optic and illumination solutions, micro sensors and high-end DSP video processors that can be tailored for both medical and industrial applications. Customization and seamless integration is at the forefront of the micro ScoutCam portfolio's design. All micro ScoutCam cameras are manufactured at Medigus' facilities, in a controlled environment, ISO 7 per the ISO 14644-1 Standard and 9001 for Quality Management System. About Medigus Medigus is a medical device company specializing in developing minimally invasive endosurgical tools and highly innovative imaging solutions. They are the pioneer developer of the MUSE™ system, an FDA cleared and CE marked endoscopic device to perform Transoral Fundoplication (TF) for the treatment of GERD (gastroesophageal reflux disease), one of the most common chronic conditions in the world. In 2016, the CMS established the Category I CPT® Code of 43210 for TF procedures, such as the ones performed with MUSE, which establishes reimbursement values for physicians and hospitals. MUSE is gaining adoption in key markets around the world -- it is available in world-leading healthcare institutions in the U.S., Europe and Israel. Medigus is also in the process of obtaining regulatory clearance in China. Medigus is traded on the Nasdaq Capital Market and the TASE (Tel-Aviv Stock Exchange). To learn more about the company's advanced technology, please visit www.medigus.com or www.RefluxHelp.com. This press release may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions and expectations of the company's management and its knowledge of the relevant market. The company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These forward-looking statements represent Medigus' expectations or beliefs concerning future events, and it is possible that the results described in this press release will not be achieved. By their nature, Forward-Looking Statements involve known and unknown risks, uncertainties and other factors which may cause future results of the company's activity to differ significantly from the content and implications of such statements. Other risk factors affecting the company are discussed in detail in the Company's filings with the Securities and Exchange Commission. Forward-Looking Statements are pertinent only as of the date on which they are made, and the company undertakes no obligation to update or revise any Forward-Looking Statements, whether as a result of new information, future developments or otherwise. Neither the company nor its shareholders, officers and employees, shall be liable for any action and the results of any action taken by any person based on the information contained herein, including without limitation the purchase or sale of company securities. Nothing in this press release should be deemed to be medical or other advice of any kind.
News Article | May 17, 2017
The worldwide market for large group physician practice computer assisted coding at $323 million in 2016, is anticipated to reach $1.1 billion by 2023. Large physician practices seek next generation computer assisted coding to support further automation of the billing process and use of analytics to achieve higher and faster payments for services rendered. The complete report provides a comprehensive analysis of Large Group Physician Practice Computer Assisted Coding in different categories, illustrating the diversity of software market segments. A complete procedure analysis is done, looking at numbers of procedures and doing penetration analysis. Major health plans report a smooth transition to ICD-10. This is due to rigorous testing for six years. ICD-10 has had a positive impact on reimbursement. ICD-10 coding system requires use of 72,000 procedure codes and 68,000 CM codes, as opposed to the 4,000 and 14,000 in the ICD-9 system. Managing high volume of codes requires automation. Healthcare providers and payers use complex coding systems, which drives demand for technologically advanced CAC systems. The market for computer-assisted coding grows because it provides management of workflow process value by encouraging increasing efficiency in care delivery for large professional physician practices and ambulatory clinical facilities. By making more granular demarcation of diagnoses and care provided for each diagnosis, greater visibility into the care delivery system is provided. Greater visibility brings more ability to adapt the system to successful treatments. Large Group Physician Practice Computer Assisted Coding Executive Summary 1. Large Physician Practice and Ambulatory Treatment Center Computer Assisted Coding Market Description and Market Dynamics 1.1 Physician Office Coding Challenge 1.1.1 Physician Practice Services Component of Computer Assisted Coding (CAC) 1.1.2 Advances In Natural Language Processing And Informatics 1.1.3 Using Electronic Health Record (EHR) Documentation To Generate Codes for Large Physician Offices 1.2 Computer-Assisted Coding 1.2.1 Physician Practice Industry Forces Affecting Development of CAC 1.2.2 Application of CAC Technology In Large Physician Offices 1.3 Development of a CAC Tool For Physician Use 1.3.1 Large Physician Office CAC Impact on the Coding Workflow 1.3.2 Computers Replace Human Coders 1.3.3 CAC Applied Without Human Intervention Depends On Critical Differences Between CAC Systems 1.4 Healthcare Industry Largest In United States 1.4.1 Building a Safer Health System 1.4.2 Facilitating the Use of Technology in the Healthcare Industry 1.4.3 Prescription Drug Modernization 1.5 Medical Necessity and Medical Necessity Errors 1.6 Physician Office Electronic Coding 1.6.1 CAC Automates and Accelerates Auditing 1.7 Natural Language Solutions 1.7.1 State Of Language Technology Evaluation 1.8 Computerized Workflow System 1.8.1 Confidence Assessment Module 1.8.2 Researching Electronic Coding Products 2. Professional Large Physician Office Computer Assisted Coding Market Shares and Forecasts 2.1.1 Physician Practices With A Services Component Market Driving Forces 2.1.2 Medical Best Practice Linking 2.1.3 Large Physician Office CAC for Coders 2.1.4 Large Physician Office Computer Assisted Coding Best Practice 2.1.5 Large Physician Office Computer Assisted Coding Medical Information Solutions 2.1.6 Large Physician Office Coding Solutions 2.1.7 Physician Computer Assisted Coding Services 2.2 Physician Office and Ambulatory Clinical Organizations Natural Language Computer Assisted Coding Market Shares 2.2.1 Optum 2.2.2 Optum Automated Code Identification 2.2.3 Optum 2.2.4 3M 2.2.5 3M 2.2.6 3M Merging Quality With Reimbursement 2.2.7 nThrive / Precyse 2.2.8 Dolbey 2.2.9 McKesson 2.2.10 Cerner 2.2.11 TruCode 2.3 Natural Language Computer Assisted Coding of Medical Procedures Forecasts 2.3.1 CAC Market Software and Services Segmentation 2.3.2 CAC Hospitals and Facilities and Physicians Market Segment 2.3.3 Computer Assisted Coding Physician Market 2.3.4 Growth of the U.S. Healthcare Industry 2.4 Making the Shift To ICD-10 Requirements 2.5 Computer Assisted Coding Prices 2.6 Computer Assisted Coding Regional Analysis 3. Computer Assisted Coding Product Description 3.1 3M 3.1.1 3M 360 Encompass System 3.1.2 3M 3M CodeAssist System 3.1.3 3M APR DRG Solutions Aspects 3.1.4 3M Merging Quality With Reimbursement 3.1.5 3M APR DRG Software 3.1.6 3 M Classification System For Patients 3.1.7 3M APR DRG Software Features: 3.1.8 3M Coding Technology 3.1.9 3M Computer-Assisted Coding Solutions 3.1.10 3M Medical Coding Tools Streamline Processes 3.1.11 CodeAssist Automating the Medical Coding Process 3.1.12 3M CodeComplete Outsource Solution for Medical Coding 3.1.13 3M DataScout Clinical Data Extraction and Identification 3.1.14 3M and American Academy of Professional Coders (AAPC) 3.1.15 3M Data Mining Technology 3.1.16 3M Systems for Overcoming Documentation Shortfalls 3.1.17 3M Solutions for a Changing Healthcare Landscape 3.1.18 3M Web-Based Coding Software Return on Investment 3.1.19 3M Coding Software Functions 3.1.20 3M Computer-Assisted Coding Solutions Targeted to Specialty Areas 3.1.21 3M CodeAssist Functions 3.1.22 3M CodeComplete Business Process Management 3.2 Dolbey 3.2.1 Dolbey Coding Productivity Management 3.2.2 Dolby Fusion Suite Modules 3.3 Optum Coding Service 3.3.1 Optum Coding 3.3.2 Optum CPT® Codes 3.3.3 Optum Medicare Fee Schedule 3.4 McKesson 3.4.1 Mckesson Watching the Cash 3.4.2 McKesson Securing the Subsidy 3.4.3 McKesson Quality Control And Process Improvement 3.5 Cerner Computer Assisted Coding 3.6 Platocode® Computer-Assisted Coding 3.6.1 Platocode ICD 10 3.6.2 Platocode® Solution For Ambulatory Surgery 3.6.3 Platocode® API 3.6.4 Communication Between 3rd-Party Applications And A Platocode Server 3.7 Nuance Computer Assisted Coding 4. Computer Assisted Coding Research and Technology 4.1 Computer-Assisted Coding Technology 4.2 Hybrid Technology 4.2.1 Computer Assisted Coding Engine 4.3 Optum Computer Assisted Coding Technology 4.4 Natural Language Processing (NLP) Medical Coding 4.4.1 Rules Based Approaches 4.4.2 Reports Based On Statistics 4.4.3 Normalize the Data 4.5 Reports Must Be In Some Kind Of Electronic Format 4.5.1 NLP Software Statistical Analysis 4.5.2 Workflow 4.5.3 Feedback for Machine Learning 4.5.4 Coding 4.5.5 Accuracy And Specificity Of Retrieval 4.5.6 Natural Language Programming (NLP) Vocabulary Processor 4.5.7 Robust Underlying Terminological Model And A Component Architecture 4.6 TeSSI® (Terminology Supported Semantic Indexing) 4.6.1 L&C's LinkBase® Medical Ontology 4.6.2 Semantic Indexing With The TeSSI® Indexing Engine 4.6.3 Semantic Indexing Solution Automates The Indexing Process 4.6.4 Information Extraction with TeSSI® Extraction Engine 4.6.5 Semantic Search with TeSSI® Search Engine 5. Computer Assisted Coding Company Profiles 5.1 CAC Key Market Players 5.2 3M 5.2.1 3M Business 5.2.2 3M Health Care Segment 5.2.3 3M Electronics and Energy Business 5.2.4 3M Health Information Systems 5.3 Cerner 5.3.1 Cerner Business 5.3.2 Cerner Acquired Siemens Health Services 5.3.3 Cerner 2016 Fourth Quarter and Full-Year Highlights: 5.4 Dolbey 5.5 EPIC 5.6 Group One / CodeCorrect 5.7 M*Modal 5.8 nThrive 5.8.1 nThrive / Precyse 5.9 Nuance 5.9.1 Nuance Healthcare 5.9.2 Nuance Business Description 5.9.3 Nuance Key Metrics 5.9.4 Nuance Healthcare Trends 5.10 Quest Diagnostics 5.11 TruCode 5.12 UnitedHealth Group / Optum 5.12.1 UnitedHealth Group / Optum 5.12.2 UnitedHealth Group Optum Health Information Technology Acquires Clinical Data Analytics Vendor Humedica 5.12.3 Optum Acquires Physician Practice Management And Revenue Management Software Firm, MedSynergies and Support Arm of ProHealth Physicians Group 5.12.4 Optum MedSynergies Synergies 5.12.5 Optum Life Sciences 5.12.6 United Healthcare Revenue 5.13 Selected CAC Companies For more information about this report visit http://www.researchandmarkets.com/research/s4j7g5/large_group To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/large-group-physician-practice-computer-assisted-coding-for-professionals-market-report-2016-2023-shares-strategies-and-forecasts-for-the-11-billion-market---research-and-markets-300459148.html